Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
15-04-21	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
15-04-21	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
15-04-08	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
15-03-05	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
15-03-05	Wall Street closes up slightly ahead of jobs report	RE
15-03-05	AbbVie : CEO says new form of Humira could thwart generics	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-03-05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
14-06-02	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

16-01-07	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
16-01-07	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
16-01-07	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

15-03-05	Wall Street se reprend un peu dans un climat d'attente
15-03-05	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
15-03-05	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	2013-01-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.85%	+4.67%	+3.39%	+25.12%	51.21B
REVOLUTION MEDICINES, INC.	+1.01%	-0.20%	+471.68%	+564.93%	45.35B
IQVIA HOLDINGS INC.	+0.16%	+7.88%	+36.14%	+20.76%	42.84B
BEONE MEDICINES AG	-0.66%	+2.61%	+18.59%	+87.04%	42.29B
CELLTRION, INC.	+0.88%	-3.48%	+17.20%	+53.83%	32.15B
MEDPACE HOLDINGS, INC.	-0.12%	+3.84%	+33.73%	+145.25%	17.31B
ASCENDIS PHARMA A/S	-0.53%	+1.84%	-	-	16.55B
EUROFINS SCIENTIFIC SE	+0.35%	+5.54%	+10.16%	+31.61%	14.84B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.15%	+4.17%	+84.49%	+50.33%	14.25B
Average	+0.35%	+3.23%	+84.42%	+122.36%	30.75B
Weighted average by Cap.	+0.39%	+3.07%	+101.41%	+141.82%

Employees

Sector